Citius Oncology Raises $18 Million in Concurrent Registered Direct Offering and Private Placement

Citius Oncology has closed an $18 million concurrent registered direct offering and private placement, priced at-the-market under Nasdaq rules. The company issued 1.28 million shares of common stock at $1.09 per share, along with unregistered warrants to purchase up to 1.28 million shares. The proceeds will support the commercial launch of LYMPHIR and for working capital and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for the offerings.